Recently diagnosed with HIV? Click here

TROP - low bone mineral density

Clinical trial • Enrolling • 22 January 2010
This trial is enrolling now. Depending on eligibility and available places in your area, you may be able to enrol in this trial.

About this trial

The purpose of this study is to see whether your bone mineral density improves when you switch from tenofovir (a NNRTI) to raltegravir (an integrase inhibitor). The theory is that people who shows signs of osteopenia will see some improvement when they switch from a regimen of tenofovir and a ritonavir-boosted protease inhibitorA type of anti-HIV drug that works by preventing the production of an enzyme, protease, that HIV needs to replicate. to one including raltegravir.

Official title:Switch From Tenofovir to Raltegravir for Low Bone Mineral Density
What is this trial studying?Treatment strategy – raltegravir
Start date:January 2010

This may be the proposed or expected start date for trials which have not yet started.

How many participants will this trial enrol?36

The exact number of participants may be lower or slightly higher than this. Some trials also have specific quotas for participants from each state, city or clinic.

How long is this trial planned to go for?Participants in this trial will be asked to follow the treatment strategy for 48 weeks.
Links to further information:
Tags:bone disorders, integrase inhibitor, raltegravir

Who can enrol in this trial?

You may be eligible to participate in this trial if you meet the following criteria:

  • At least 18 years old
  • Currently taking HIV treatments
  • Viral load below 50 copies/ml
  • Currently taking tenofovir and a ritonavir boosted PI and have been diagnosed with osteopenia

This is a summary of key inclusion and exclusion criteria for this trial. There may be other criteria which may exclude some people from participation in this trial. Some laboratory tests may also be required. Consult your doctor, or view the trial protocol or informed consent documentation to see the full range of exclusion and inclusion criteria.

If you are interested in enrolling in this trial

Before making the decision to participate in any clinical trial, NAPWA recommends that you discuss the potential benefits and risks of participation with your treating doctor. Your doctor can also provide advice about your eligibility to participate in the trial.

While NAPWA has taken every care to compile the information on this page and to keep it up-to-date, we cannot guarantee its correctness and completeness.

  • You can print this page to take it with you to the doctor – just use your browser's 'print' function.
  • Before making the decision to participate in any clinical research, read our background information.
  • Email NAPWA if you have any questions or comments about this trial
Text size: font smallerfont normalfont larger print-friendly version of this pagePDF version of this pageemail this page to a friend

This Clinical trial was first published on 22 January 2010.

While the content of this clinical trial was checked for accuracy at the time of publication, NAPWA recommends checking to determine whether the information is the most up-to-date available, especially when making decisions which may affect your health.

This article may contain medical information. NAPWA makes every reasonable effort to ensure the information on this website is accurate, reliable and up-to-date, including obtaining technical reviews by medically-qualified reviewers, however the authors of information on this website are not qualified to give medical advice, except where explicitly stated.

The content of this website is intended to support, not replace, the relationship between people living with HIV/AIDS and their medical advisers, and is not intended as a substitute for medical advice.

Website links

HIV Clinical Trials update

Recently updated entries from the NAPWA Clinical Trials database.

more